What is HC Wainwright’s Estimate for Compugen Q1 Earnings?

Compugen Ltd. (NASDAQ:CGEN) – Equities research analysts at HC Wainwright issued their Q1 2026 earnings estimates for shares of Compugen in a research note issued on Tuesday, March 3rd. HC Wainwright analyst S. Ramakanth forecasts that the biotechnology company will post earnings per share of ($0.09) for the quarter. HC Wainwright has a “Buy” rating and a $4.00 price objective on the stock. The consensus estimate for Compugen’s current full-year earnings is ($0.03) per share. HC Wainwright also issued estimates for Compugen’s Q2 2026 earnings at ($0.09) EPS, Q3 2026 earnings at ($0.09) EPS, Q4 2026 earnings at ($0.09) EPS and FY2026 earnings at ($0.36) EPS.

Compugen (NASDAQ:CGEN) last announced its quarterly earnings results on Monday, March 2nd. The biotechnology company reported $0.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.05 by $0.55. The company had revenue of $67.33 million for the quarter, compared to the consensus estimate of $14.30 million. Compugen had a return on equity of 55.68% and a net margin of 48.57%.

Several other brokerages have also commented on CGEN. Weiss Ratings restated a “sell (d-)” rating on shares of Compugen in a report on Wednesday, January 21st. Wall Street Zen upgraded Compugen from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Compugen presently has a consensus rating of “Hold” and a consensus target price of $4.00.

Compugen Stock Performance

Shares of NASDAQ CGEN opened at $2.14 on Thursday. The firm has a fifty day simple moving average of $1.82 and a two-hundred day simple moving average of $1.66. Compugen has a 12 month low of $1.13 and a 12 month high of $2.38.

Institutional Investors Weigh In On Compugen

Institutional investors have recently made changes to their positions in the company. XTX Topco Ltd bought a new position in Compugen in the 4th quarter valued at approximately $104,000. Bank Hapoalim BM purchased a new position in shares of Compugen in the fourth quarter worth $37,000. Security National Bank of Sioux City Iowa IA purchased a new position in shares of Compugen in the fourth quarter worth $38,000. Marshall Wace LLP lifted its holdings in shares of Compugen by 135.7% during the fourth quarter. Marshall Wace LLP now owns 106,304 shares of the biotechnology company’s stock valued at $163,000 after purchasing an additional 61,202 shares in the last quarter. Finally, State Street Corp increased its holdings in Compugen by 3.9% in the 4th quarter. State Street Corp now owns 393,802 shares of the biotechnology company’s stock worth $603,000 after buying an additional 14,701 shares in the last quarter. Hedge funds and other institutional investors own 12.22% of the company’s stock.

About Compugen

Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.

Compugen’s predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.